# Jean-Philippe Tripet

> Jean-Philippe Tripet is a Series A investor at Aravis Ventures backing Biopharma and Health Care. See 3 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Aravis Ventures](https://shizune.co/investors/profile/aravis-ventures)
- Total investments: 3
- Last investment: Dec 2013
- Lead investor: 33%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/tripet-jean-philippe-687b20192

Jean-Philippe Tripet is a Series A investor at Aravis Ventures focused on Biopharma and Health Care. Jean-Philippe Tripet, managing partner and founder of Aravis, has over 15 years experience as portfolio manager and financial analyst. In 1994 he co-founded the Lombard Odier Immunology fund that became one of the most successful healthcare funds in Europe under his supervision. He has supervised over 70 private investments. Since 1994Jean-Philippe Tripet has participated actively to the launch and financing of many successful start-up companies such as Modex, Novimmune, Cytos, Genedata, Esbatech and Novalon. He is a member of the board of directors of Evolva, MerLion, Symetis Omeros, S Bio, TelorMedix and Synosia. He has a degree in business administration from the University of Geneva, did graduate studies in San Diego (USA) and is a Chartered Financial Analyst.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biopharma | 1 | 33% |
| Health Care | 1 | 33% |
| Therapeutics | 1 | 33% |
| Biotechnology | 1 | 33% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 1 | 33% |
| Series B | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Telormedix | Telormedix is a biopharmaceutical company focused on targeted immunity and the role of the innate immune system in treating cancer and autoimmune diseases. | $6.8M | Series B | Dec 02, 2013 |  |
| Telormedix | Telormedix is a biopharmaceutical company focused on targeted immunity and the role of the innate immune system in treating cancer and autoimmune diseases. | $7M | Series B | Jan 25, 2012 |  |
| Telormedix | Telormedix is a biopharmaceutical company focused on targeted immunity and the role of the innate immune system in treating cancer and autoimmune diseases. | $19M | Series A | Sep 30, 2008 |  |

3 of 3 investments shown.

## Co-investors
- [ProQuest Investments](https://shizune.co/investors/profile/proquest-investments) — VC Fund, 3 deals together
- [BSI SA](https://shizune.co/investors/profile/bsi-sa) — VC Fund, 1 deal together
- [Nextech Invest](https://shizune.co/investors/profile/nextech-invest) — VC Fund, 1 deal together

## About Aravis Ventures

VC Fund · Zürich, Switzerland

Aravis is the first independent Swiss on-shore private equity house, an established investor in the renewable energy and life science spaces. We are a "hands-on" investor taking leading positions and understanding the balance between finance, commercial assets and people. With this distinct and crafted approach, we are serving over 30leading investors including corporates, pension funds, government funds, insurance companies and family offices. Currently actively managing more than a quarter of a billion Swiss francs, we have a cumulative history of investments in over 100 companies. These have resulted in several noticeable exits including the divestment of several renewable energy companies and a number of life science reverse take-overs, listings and trade sales. Our many years of experience in the Swiss fund industry have enabled us to establish a platform with a comprehensive offering of investment, accounting, regulatory and reporting expertise. Located in Zurich, Aravis was founded in 2001.

5 contacts available at Aravis Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| Jean-Philippe Tripet | Founder and Chairman | https://shizune.co/investors/profile/jean-philippe-tripet |
| Andreas Jacobs | Managing Partner & CFO | https://shizune.co/investors/profile/andreas-jacobs |
| Kadri Vunder | Investment Manager | https://shizune.co/investors/profile/kadri-vunder |
| Marc Krattinger | Partner | https://shizune.co/investors/profile/marc-krattinger |
| Margaretha Bruelisauer | Accountant | https://shizune.co/investors/profile/margaretha-bruelisauer |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Jean-Philippe Tripet invest in?

Jean-Philippe Tripet invests primarily in Biopharma, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 3 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Jean-Philippe Tripet last invest?

The most recent investment recorded for Jean-Philippe Tripet closed in Dec 2013. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co